Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVID-19 Immunologic Antiviral Therapy With Omalizumab - An Adaptive Phase II Randomized-Controlled Clinical Trial

NCT04720612 is registered in ClinicalTrials.gov with McGill University Health Centre/Research Institute of the McGill University Health Centre as lead sponsor.

NCT NCT04720612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04720612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVID-19 Immunologic Antiviral Therapy With Omalizumab - An Adaptive Phase II Randomized-Controlled Clinical Trial
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase
Phase 2
Overall status
Unknown status
Start date
October 15, 2021
Completion date
December 16, 2022
Enrollment
40 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid19